Ziopharm Oncology News
Most Popular Ziopharm Oncology Story
Ziopharm soars on promising cancer data
Shares of Ziopharm Oncology zoomed up 37 percent this morning after the developer released promising mid-stage data on its cancer drug Zymafos. The company decided to stop enrolling new patients into... Read more...
Latest Headlines
- October 14, 2009
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
